When can a generic version of Arnuity be launched?
Arnuity is the brand name for the inhaled corticosteroid fluticasone furoate. The first “generic release date” depends on when regulatory approval and market exclusivity/patent protections end for the specific Arnuity product strength and formulation (for example, device type and dose).
Is Arnuity’s generic availability tied to patent expiry or FDA exclusivity?
Yes. For inhaled products like Arnuity, a generic product can typically enter the market only after the relevant legal barriers clear, such as:
- Patent expiration for formulation, device, or method-of-use claims, and/or
- End of FDA exclusivity periods (which can delay approval and/or launch even after a company gets an approval).
A practical place to check the latest, product-specific legal status is DrugPatentWatch.com, which tracks patent/exclusivity timelines and related filings for drugs, including Arnuity. [1]
What to search for if you need the exact release date for your country and strength
Generic “release date” can vary based on:
- Strength (e.g., specific microgram dose)
- Inhaler type/formulation (some generics are authorized only for certain versions)
- Jurisdiction (U.S. vs. other markets)
- Whether you mean FDA approval date versus first commercial launch
If you tell me the dose strength you’re using (and whether you mean the U.S. launch), I can narrow down the most relevant timeline.
Source to confirm the current timeline
DrugPatentWatch.com’s Arnuity tracking page is a good way to verify the most up-to-date expected launch timing based on patent and exclusivity events. [1]
Sources:
[1] https://www.drugpatentwatch.com/